News | January 12, 2009

Micell Forms Alliance for the Development of Drug-Eluting Stents, Balloons

January 13, 2009 - Micell Technologies, a development-stage biomedical device company dedicated to developing innovative interventional cardiology systems, has obtained the rights to Maxcor's CE-marked Genius MAGIC Cobalt Chromium Coronary Stent System for the purpose of developing and marketing drug-eluting stents (DES) based on Micell's prop coating technology.

The companies also entered into an agreement to develop drug-eluting balloon (DEB) products for cardiovascular applications.

Micell has developed a drug-polymer formulation that is said to precisely and consistently control drug elution and the duration of polymer exposure. The coating has the potential to deliver a precise therapeutic solution for coronary artery disease without the long-term safety concerns of currently available DES. The in-licensing of the Genius MAGIC Cobalt Chromium Coronary Stent System provides what the company believes is the optimal bare-metal stent product for the further development of the company's drug-polymer coating. The company believes that DEB will advance the treatment of many clinical conditions while minimizing risks or side-effects of these treatments.

For more information: www.micell.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Spectranetics Announces FDA Approval of Stellarex Drug-Coated Balloon
Technology | Drug-Eluting Balloons| July 26, 2017
The Spectranetics Corp. announced receipt of U.S. Food and Drug Administration (FDA) pre-market approval (PMA) of the...
Philips acquires purchases Spectranetics
Feature | Business| June 28, 2017
Philips Healthcare and Spectranetics Corp. announced they have entered into a definitive merger agreement for $2.05...
News | June 12, 2017
June 12, 2017 – Med Alliance announced completion on schedule of patient enrollment in the first-in-man (FIM) study o
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Overlay Init